Insider Buying Surge During Iran War Cycle
War cycle fuels commodity-linked insider accumulation and conviction averaging in speculative names
Director buying in Contango Silver & Gold adds to a broadening pattern of insider accumulation in commodity-linked names during the Iran war cycle. In Lipocine, a director is aggressively averaging down from $5 to $2.03, now holding 203,797 shares personally — a classic conviction signal in a clinical-stage pharmaceutical.
| Instrument | Side | Target | Reason |
|---|---|---|---|
| CTGO | Long | Stoquate suggests this director-level buy of $185,600 in Contango Silver & Gold at $18.56 fits the broader war-cycle pattern of insider accumulation in precious metals — geopolitical tailwinds combined with personal insider commitment provide a meaningful signal. | |
| LPCN | Long | Stoquate suggests attention to Lipocine where director Higuchi now personally holds 203,797 shares after buying a further 40,000 at $2.03 — averaging down from the $5 range shows genuine conviction, not a one-off purchase, in this clinical-stage pharma. |
Major CEO open-market purchases signal deep conviction in healthcare and insurance sector recovery
Mark Bertolini's $11.92M purchase of Oscar Health is the largest single CEO open-market buy of the war cycle, signaling strong conviction in the company's path to durable profitability. CEO and director buys in H.B. Fuller and Lamb Weston further confirm insider confidence across industrial and consumer staple names.
| Instrument | Side | Target | Reason |
|---|---|---|---|
| OSCR | Long | CEO Mark Bertolini — who built Aetna into one of America's most profitable health insurers — made the single largest CEO open-market purchase of the entire war cycle at $11.92M, signaling deep personal conviction in Oscar Health's transition from high-growth disruptor to durably profitable insurer. Garrett is actively looking for a spread trade. | |
| FUL | Long | Stoquate suggests considering CEO Celeste Beeks Mastin's $295K indirect purchase as a signal of confidence in H.B. Fuller's multi-year margin improvement program, indicating management believes execution is on track. | |
| LW | Long | Stoquate suggests monitoring Lamb Weston as a contrarian insider signal — director buying at $39.45 amid sustained volume declines and margin compression may indicate the worst is already priced in for the frozen potato category leader. |
Themes
The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.